



Newly Reported Drugs: The following drugs were reported to NFLIS-Drug for the first time between **October 1, 2020, and December 31, 2020.**

<p>West</p> <div style="border: 1px solid black; padding: 5px;"> <p>4F-MDMB-BUTICA</p> </div>	<p>South</p> <p>2Br-4,5-Dimethoxyphenethylamine</p>	<p>Midwest</p> <div style="border: 1px solid black; padding: 5px;"> <p>4F-3-Methyl-alpha-PVP</p> </div>	<p>Northeast</p> <p>5F-EMB-PICA</p>
<div style="border: 1px solid black; padding: 5px;"> <p>4F-MDMB-BUTICA</p> </div>		<div style="border: 1px solid black; padding: 5px;"> <p>Metonitazene</p> </div>	

Snapshot of Drug Reports Received by NFLIS-Drug

The tables on the right present the top five drug reports in each category received by NFLIS-Drug between October 1, 2020, and December 31, 2020.


Top 5 Reported Drugs	255,323	Synthetic Cathinones	3,309	Benzodiazepines	11,332
Methamphetamine	108,772	Eutylone	2,745	Alprazolam	5,073
Cannabis/THC	49,337	BMDP ¹	161	Clonazepam	1,536
Cocaine	40,725	N-Ethylpentylone	90	Etizolam	1,517
Fentanyl	29,133	alpha-PHP	48	Flualprazolam	1,383
Heroin	27,356	alpha-PiHP	32	Clonazolam	767

Synthetic Cannabinoids	2,991	Fentanyl-Related Compounds	3,336	Other Selected Drugs	6,826
MDMB-4en-PINACA	1,055	ANPP	2,152	Tramadol	2,766
Fluoro-MDMB-PICA ²	843	Acetyl fentanyl	806	LSD	1,401
Fluoro-MDMB-BUTINACA ²	331	Phenethyl 4-ANPP	130	PCP	1,329
5F-ADB	75	Carfentanil	94	Gabapentin	759
FUB-AMB	28	Valeryl fentanyl	89	Xylazine	571

¹ BMDP = 3,4-Methylenedioxy-N-benzylcathinone.

² Includes all positional and nonspecified isomers as reported by participating laboratories.

Upward Trends, by Date Submitted to Laboratory³



³ NFLIS-Drug has not yet received a sufficient number of analysis results of drug submissions to laboratories in December 2020; thus, only trends through November 2020 are shown.

Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in January 2021 and include drug reports received by NFLIS-Drug through December 2020. Data in the Newly Reported Drugs and Snapshot of Drug Reports Received by NFLIS-Drug sections only include drugs submitted to laboratories on or after October 1, 2019. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.deadiversion.usdoj.gov/Reports.aspx>. Questions and comments: DEANFLIS@rti.org

